GLP-1 receptor agonist tagged posts

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.

Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).

The researchers found that at five years, patients expo...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drugs ability to lower brain fluid pressure is the key, potentially opening a completely new way to treat migraines. The effects were fast, sustained, and came with only mild side effects.

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.1

Researchers at the Headache Center of the University of Naples “Federico II” ...